2l3y: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Solution structure of mouse IL-6== | |||
<StructureSection load='2l3y' size='340' side='right' caption='[[2l3y]], [[NMR_Ensembles_of_Models | 52 NMR models]]' scene=''> | |||
=== | == Structural highlights == | ||
<table><tr><td colspan='2'>[[2l3y]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2L3Y OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2L3Y FirstGlance]. <br> | |||
</td></tr><tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">Il6, Il-6 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=10090 Mus musculus])</td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2l3y FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2l3y OCA], [http://www.rcsb.org/pdb/explore.do?structureId=2l3y RCSB], [http://www.ebi.ac.uk/pdbsum/2l3y PDBsum]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
A number of secreted cytokines, such as interleukin-6 (IL-6), are attractive targets for the treatment of inflammatory diseases. We have determined the solution structure of mouse IL-6 to assess the functional significance of apparent differences in the receptor interaction sites (IL-6Ralpha and gp130) suggested by the fairly low degree of sequence similarity with human IL-6. Structure-based sequence alignment of mouse IL-6 and human IL-6 revealed surprising differences in the conservation of the two distinct gp130 binding sites (IIa and IIIa), which suggests a primacy for site III-mediated interactions in driving initial assembly of the IL-6/IL-6Ralpha/gp130 ternary complex. This is further supported by a series of direct binding experiments, which clearly demonstrate a high affinity IL-6/IL-6Ralpha-gp130 interaction via site III but only weak binding via site II. Collectively, our findings suggest a pathway for the evolution of the hexameric, IL-6/IL-6Ralpha/gp130 signaling complex and strategies for therapeutic targeting. We propose that the signaling complex originally involved specific interactions between IL-6 and IL-6Ralpha (site I) and between the D1 domain of gp130 and IL-6/IL-6Ralpha (site III), with the later inclusion of interactions between the D2 and D3 domains of gp130 and IL-6/IL-6Ralpha (site II) through serendipity. It seems likely that IL-6 signaling benefited from the evolution of a multipurpose, nonspecific protein interaction surface on gp130, now known as the cytokine binding homology region (site II contact surface), which fortuitously contributes to stabilization of the IL-6/IL-6Ralpha/gp130 signaling complex. | |||
Conservation of functional sites on interleukin-6 and implications for evolution of signaling complex assembly and therapeutic intervention.,Veverka V, Baker T, Redpath NT, Carrington B, Muskett FW, Taylor RJ, Lawson AD, Henry AJ, Carr MD J Biol Chem. 2012 Nov 16;287(47):40043-50. doi: 10.1074/jbc.M112.405597. Epub, 2012 Oct 1. PMID:23027872<ref>PMID:23027872</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
==See Also== | ==See Also== | ||
*[[Interleukin|Interleukin]] | *[[Interleukin|Interleukin]] | ||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Mus musculus]] | [[Category: Mus musculus]] | ||
[[Category: Carr, M D | [[Category: Carr, M D]] | ||
[[Category: Carrington, B | [[Category: Carrington, B]] | ||
[[Category: Henry, A J | [[Category: Henry, A J]] | ||
[[Category: Muskett, F W | [[Category: Muskett, F W]] | ||
[[Category: Redpath, N T | [[Category: Redpath, N T]] | ||
[[Category: Taylor, R J | [[Category: Taylor, R J]] | ||
[[Category: Veverka, V | [[Category: Veverka, V]] | ||
[[Category: Cytokine]] | [[Category: Cytokine]] | ||
[[Category: Gp-130]] | [[Category: Gp-130]] | ||
Revision as of 13:57, 17 December 2014
Solution structure of mouse IL-6
| ||||||||||||